Duke Clinical Research Institute, Durham, North Carolina; University of Alberta, Edmonton, Alberta, Canada.
Duke Clinical Research Institute, Durham, North Carolina.
JACC Cardiovasc Interv. 2018 Sep 24;11(18):1837-1847. doi: 10.1016/j.jcin.2018.07.020.
The aim of this study was to describe the prevalence of pre-hospital cardiac catheterization laboratory activation and its association with reperfusion timeliness and in-hospital mortality.
For patients with ST-segment elevation myocardial infarction diagnosed in the field, catheterization laboratory pre-activation may lead to more timely reperfusion and improved outcomes.
A total of 27,840 patients with ST-segment elevation myocardial infarction transported via emergency medical services to 744 percutaneous coronary intervention-capable hospitals in the ACTION Registry from January 2015 to March 2017 were evaluated, excluding patients with cardiac arrest or requiring pre-percutaneous coronary intervention intubation. Catheterization laboratory pre-activation was defined as activation >10 min prior to hospital arrival.
Catheterization laboratory pre-activation occurred in 41% of patients (n = 11,379), with minor presenting differences between those with and without catheterization laboratory pre-activation. Compared with no catheterization laboratory pre-activation, pre-activation patients were more likely to be directly transported to the catheterization laboratory on hospital arrival (23.3% vs. 5.3%), to have shorter hospital arrival-to-catheterization laboratory arrival time (median 17 min [interquartile range (IQR): 7 to 25 min] vs. 28 min [IQR: 18 to 39 min]), to have shorter door-to-device time (40 min [IQR: 30 to 51 min] vs. 52 min [IQR: 41 to 65 min]), and to have a greater likelihood of achieving first medical contact-to-device time ≤90 min (76.6% vs. 68.6%) (p < 0.001 for all). Pre-activation was associated with lower in-hospital mortality (2.8% vs. 3.4%; p = 0.01). Patients treated at hospitals in the lowest tertile of pre-activation rates had higher mortality than those treated at hospitals in the highest tertile before and after adjustment (3.6% vs. 2.7%; adjusted odds ratio: 1.33; 95% confidence interval: 1.08 to 1.63).
In the United States, catheterization laboratory pre-activation occurred in fewer than one-half of emergency medical services-transported patients with ST-segment elevation myocardial infarction. Its association with faster reperfusion and lower mortality supports greater use of this strategy.
本研究旨在描述院前心脏导管实验室激活的流行情况及其与再灌注时间和院内死亡率的关系。
对于在现场诊断为 ST 段抬高型心肌梗死的患者,导管实验室的预先激活可能会导致更及时的再灌注和更好的结果。
对 2015 年 1 月至 2017 年 3 月 ACTION 登记处 744 家可进行经皮冠状动脉介入治疗的医院通过急诊医疗服务转运的 27840 例 ST 段抬高型心肌梗死患者进行评估,排除心脏骤停或需要经皮冠状动脉介入术前插管的患者。导管实验室的预先激活被定义为在到达医院前 10 分钟以上进行激活。
41%(n=11379)的患者进行了导管实验室的预先激活,有导管实验室预先激活和没有导管实验室预先激活的患者在表现上存在细微差异。与没有导管实验室预先激活的患者相比,预先激活的患者更有可能在到达医院时直接被转运至导管实验室(23.3%比 5.3%),到达医院至到达导管实验室的时间更短(中位数 17 分钟[四分位距(IQR):7 至 25 分钟]比 28 分钟[IQR:18 至 39 分钟]),门到设备的时间更短(40 分钟[IQR:30 至 51 分钟]比 52 分钟[IQR:41 至 65 分钟]),并且更有可能实现首次医疗接触到设备的时间≤90 分钟(76.6%比 68.6%)(所有 p 值均<0.001)。预先激活与院内死亡率降低相关(2.8%比 3.4%;p=0.01)。在调整前后,在预先激活率最低的三分之一医院接受治疗的患者的死亡率高于在预先激活率最高的三分之一医院接受治疗的患者(3.6%比 2.7%;调整后的优势比:1.33;95%置信区间:1.08 至 1.63)。
在美国,不到一半的通过急诊医疗服务转运的 ST 段抬高型心肌梗死患者进行了导管实验室的预先激活。其与更快的再灌注和更低的死亡率相关,支持更广泛地使用这种策略。